Most European Countries Lack Evidence-Based Cannabis-Specific Treatment
A pan-European mapping study surveying 30 countries finds that only half have structured cannabis-specific treatment programs, most with limited geographic coverage, weak evidence bases, and insufficient services for high-risk populations including adolescents and those with psychiatric comorbidities.
Why This Matters
Cannabis use disorder is the most common reason for first-time drug treatment admissions across Europe, with roughly 92,000 entries recorded in 2022 alone. Despite this clinical burden, there has been no systematic accounting of what cannabis-specific services actually exist on the ground since 2015. As several European nations liberalize cannabis policy, the gap between rising treatment demand and available, evidence-based clinical infrastructure becomes a pressing public health concern that clinicians, administrators, and policymakers urgently need to understand.
Clinical Summary
Cannabis use disorder affects an estimated 8 to 22 percent of lifetime cannabis users, and cannabis-related treatment entries now represent 36 percent of all drug treatment admissions in Europe. This cross-sectional mapping study, published in 2025 and conducted under the auspices of the European Union Drugs Agency, surveyed National Focal Points in 30 countries using a combination of internal Drug and Treatment Workbooks and a custom five-item questionnaire distributed in 2022 and 2023. The study aimed to catalogue structured, theory-driven, cannabis-specific treatment programs rather than to assess their effectiveness. The mechanistic premise is straightforward: cannabis use disorder is a distinct clinical entity requiring targeted psychosocial intervention, yet most European treatment systems have historically embedded cannabis within general substance use frameworks without disorder-specific programming.
Of the 30 countries surveyed, 16 reported at least one structured cannabis-specific program. Face-to-face interventions were available in 15 countries, though most described their geographic coverage as “limited.” Web-based programs such as CANreduce, Quit the Shit, and VALIK expanded during the COVID-19 pandemic and now operate in at least nine countries, offering greater scalability particularly for rural populations. Specialized services for adolescents and individuals with comorbid psychiatric conditions remain rare, with dedicated cannabis clinics addressing dual diagnosis having opened only recently in Belgium, Romania, and the United Kingdom. Critically, most programs were not described as evidence-based, and no approved pharmacotherapy for cannabis use disorder exists. The authors emphasize that structured psychosocial approaches including cognitive behavioral therapy, motivational enhancement therapy, and contingency management carry the strongest evidence, and they call for expanded investment in both validated programming and outcome research before clinical recommendations can be generalized across European health systems.
Dr. Caplan’s Take
This study does something deceptively simple but genuinely valuable: it asks what actually exists. Patients with cannabis use disorder frequently present to our clinic asking about treatment options, and the honest answer in most jurisdictions is that structured, cannabis-specific programming is either unavailable or untested. What this mapping exercise confirms is that the treatment infrastructure has not kept pace with either the epidemiology or the evolving policy landscape. The gap between what we know works in controlled research settings and what is actually deployed at scale is substantial.
In practice, I approach cannabis use disorder with structured psychosocial interventions, primarily motivational interviewing and cognitive behavioral strategies, because these have the most consistent evidence. For patients with co-occurring psychiatric conditions, integrated treatment planning is essential, and I refer to specialized dual-diagnosis services where they exist. I also discuss digital tools as adjuncts, particularly for patients facing geographic or scheduling barriers, while being transparent that most of these platforms lack rigorous outcome data. The key clinical move is not to wait for a perfect evidence base but to use the best available tools while acknowledging their limitations honestly.
Clinical Perspective
This study sits at the descriptive, early-stage end of the research arc. It does not evaluate whether any specific program works; rather, it establishes the baseline of what is available. For clinicians, this distinction is critical. The finding that most existing programs are not formally evidence-based does not mean they are ineffective, but it does mean that recommending any particular national program to a patient cannot be grounded in robust outcome data. The study confirms what structured reviews of psychosocial treatments have shown: cognitive behavioral therapy, motivational enhancement therapy, and contingency management remain the best-supported modalities. What it adds is the sobering context that these approaches are not reaching most patients who need them.
From a pharmacological standpoint, the study reiterates the absence of any approved medication for cannabis use disorder, which distinguishes this condition from alcohol, opioid, and tobacco use disorders where pharmacotherapy plays a well-defined role. Clinicians should be aware that off-label agents sometimes discussed in literature, such as N-acetylcysteine or gabapentin, lack sufficient evidence to support routine recommendation. The single most actionable step a clinician can take today is to systematically screen for cannabis use disorder using validated instruments and refer to structured psychosocial treatment where available, while documenting the gap when it is not, because that documentation is precisely the kind of data health systems need to justify expanded programming.
Study at a Glance
- Study Type
- Cross-sectional descriptive mapping study (mixed methods)
- Population
- 30 European countries (27 EU member states plus the UK, Norway, and Turkey)
- Intervention
- Not applicable; study maps existing cannabis-specific treatment programs
- Comparator
- None; descriptive design
- Primary Outcomes
- Availability, type, and geographic coverage of structured cannabis-specific treatment programs
- Sample Size
- 30 countries surveyed via National Focal Points
- Journal
- Published 2025 (specific journal not specified in source data)
- Year
- 2025
- DOI or PMID
- Not available
- Funding Source
- European Union Drugs Agency (EUDA)
What Kind of Evidence Is This
This is a cross-sectional descriptive mapping study using a mixed-methods design that combines analysis of internal agency workbooks with a custom survey distributed to national informants across 30 European countries. It sits near the bottom of the evidence hierarchy for clinical decision-making because it does not evaluate treatment effectiveness or patient outcomes. The most important inference constraint is that the study can describe what exists but cannot tell us whether any of it works.
How This Fits With the Broader Literature
This study updates and extends a 2015 EMCDDA report that was, until now, the most recent pan-European accounting of cannabis-specific treatment availability. The finding of incremental but insufficient progress aligns with broader observations in the addiction treatment literature that service development for cannabis use disorder has lagged behind other substance use disorders. Systematic reviews of cannabis-specific psychosocial treatments, such as the Cochrane review by Gates and colleagues, have consistently found that CBT, motivational enhancement therapy, and contingency management produce modest but significant reductions in cannabis use, yet the current mapping study reveals that these validated approaches are not being deployed at scale in most European countries.
The expansion of digital and web-based interventions documented here mirrors trends in other behavioral health fields and represents the most notable shift since the 2015 baseline. However, platforms like CANreduce, while promising in pilot evaluations, have not yet undergone the kind of large-scale effectiveness testing that would support definitive clinical endorsement.
Common Misreadings
The most likely overinterpretation is to conclude that European countries without cannabis-specific programs have no treatment options for cannabis use disorder. In reality, many countries provide cannabis-related care within general substance use treatment settings; what this study captures is the absence of structured, cannabis-specific programming, which is a narrower and more precise claim. Equally, the finding that most existing programs lack an evidence base should not be read as evidence of ineffectiveness. It indicates that rigorous evaluation has not been conducted, which is a gap in knowledge rather than a demonstrated failure of care.
Bottom Line
This mapping study establishes that cannabis-specific treatment infrastructure across Europe is fragmented, geographically limited, and largely unevaluated. It does not tell us which programs work or how patient outcomes vary across settings. For clinicians, the immediate practical implication is to rely on the psychosocial modalities with the strongest independent evidence, screen systematically, and advocate within health systems for the kind of structured, evaluated programming that this study reveals to be missing.
References
- European Union Drugs Agency (EUDA). Cannabis-specific treatment programs in Europe: a pan-European mapping study. 2025.
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Treatment of cannabis-related problems in Europe. EMCDDA Insights, 2015.
- Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database of Systematic Reviews. 2016;(5):CD005336. DOI: 10.1002/14651858.CD005336.pub4
- Schaub MP, Wenger A, Berg O, et al. A web-based self-help intervention with and without chat counseling to reduce cannabis use in problematic cannabis users: three-arm randomized controlled trial (CANreduce). Journal of Medical Internet Research. 2015;17(10):e232. DOI: 10.2196/jmir.4860
Have thoughts on this? Share it:
